

## SEQUENCE LISTING

<110> SUMITOMO PHARMACEUTICALS COMPANY, LIMITED  
SAITO, Izumi  
SAITO, Yumi

<120> DNA Containing Variant FRT Sequence

<130> 1422-0527P

<140> US 10/089,380

<141> 2002-03-29

<150> JP 11-280210

<151> 1999-09-30

<150> JP 11-346727

<151> 1999-12-06

<150> PCT/JP00/06686

<151> 2000-09-28

<160> 36

<210> 1

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 1

gaagttccta tactttctag agaataggaa cttc

34

<210> 2

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 2

gaagttccta tactctctgg agaataggaa cttc

34

<210> 3

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 3

gaagttccta tactctccag agaataggaa cttc

34

<210> 4

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 4

gaagttccta tactatcttg agaataggaa cttc

34

<210> 5

<211> 34  
<212> DNA  
<213> *Saccharomyces cerevisiae*

<400> 5  
gaagttccta tactttctgg agaataggaa cttc 34

<210> 6  
<211> 34  
<212> DNA  
<213> *Saccharomyces cerevisiae*

<400> 6  
gaagttccta tactatttga agaataggaa cttc 34

<210> 7  
<211> 34  
<212> DNA  
<213> *Saccharomyces cerevisiae*

<400> 7  
gaagttccta taccttgtga agaataggaa cttc 34

<210> 8  
<211> 34  
<212> DNA  
<213> *Saccharomyces cerevisiae*

<400> 8  
gaagttccta tactatctac agaataggaa cttc 34

<210> 9  
<211> 34  
<212> DNA  
<213> *Saccharomyces cerevisiae*

<400> 9  
gaagttccta tactgtctat agaataggaa cttc 34

<210> 10  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> The oligonucleotide is synthesized DNA adaptor.

<400> 10  
agcttctgca gcagaccgtg catcatg 27

<210> 11  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> The oligonucleotide is synthesized DNA adaptor.

<400> 11  
atgcacggtc tgctgcaga 19

<210> 12  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on wild type FRT sequence.

<400> 12  
tcgaggacgt cgaagttcct atactttcta gagaatagga acttctccgg aa 52

<210> 13  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on wild type FRT sequence.

<400> 13  
ctagttccgg agaagttcct attctctaga aagtatagga acttcgacgt cc 52

<210> 14  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 14  
tcgaggacgt cgaagttcct atactatcta gagaatagga acttctccgg aa 52

<210> 15  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 15  
tcgaggacgt cgaagttcct atactttctg gagaatagga acttctccgg aa 52

<210> 16  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 16

tcgaggacgt cgaagttcct atactttcta cagaatagga acttctccgg aa 52

<210> 17  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 17  
tcgaggacgt cgaagttcct atactatttg aagaatagga acttctccgg aa 52

<210> 18  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 18  
tcgaggacgt cgaagttcct atactctctg gagaatagga acttctccgg aa 52

<210> 19  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 19  
tcgaggacgt cgaagttcct atactatcta cagaatagga acttctccgg aa 52

<210> 20  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 20  
tcgaggacgt cgaagttcct atactctcca gagaatagga acttctccgg aa 52

<210> 21  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 21  
tcgaggacgt cgaagttcct atactatctt gagaatagga acttctccgg aa 52

<210> 22  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 22  
tcgaggacgt cgaagttcct atactgtcta tagaatagga acttctccgg aa 52

<210> 23  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 23  
ctagttccgg agaagttcct attctctaga tagtatagga acttcgacgt cc 52

<210> 24  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 24  
ctagttccgg agaagttcct attctccaga aagtatagga acttcgacgt cc 52

<210> 25  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 25  
ctagttccgg agaagttcct attctgtaga aagtatagga acttcgacgt cc 52

<210> 26  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 26  
ctagttccgg agaagttcct attcttcaaa tagtatagga acttcgacgt cc 52

<210> 27  
<211> 52

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide based on mutant FRT sequence.

&lt;400&gt; 27

ctagttccgg agaagttcct attctccaga gagtatagga acttcgacgt cc 52

&lt;210&gt; 28

&lt;211&gt; 52

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide based on mutant FRT sequence.

&lt;400&gt; 28

ctagttccgg agaagttcct attctgtaga tagtatagga acttcgacgt cc 52

&lt;210&gt; 29

&lt;211&gt; 52

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide based on mutant FRT sequence.

&lt;400&gt; 29

ctagttccgg agaagttcct attctctgga gagtatagga acttcgacgt cc 52

&lt;210&gt; 30

&lt;211&gt; 52

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide based on mutant FRT sequence.

&lt;400&gt; 30

ctagttccgg agaagttcct attctcaaga tagtatagga acttcgacgt cc 52

&lt;210&gt; 31

&lt;211&gt; 52

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide based on mutant FRT sequence.

&lt;400&gt; 31

ctagttccgg agaagttcct attctataga cagtatagga acttcgacgt cc 52

&lt;210&gt; 32

&lt;211&gt; 34

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide based on mutant FRT sequence.

&lt;400&gt; 32

gaagttccta tactttctac agaataggaa cttc

34

&lt;210&gt; 33

&lt;211&gt; 54

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide based on FLP recognition sequence.

&lt;400&gt; 33

aaattcggga gaagttccta ttctctagaa agtataggaa cttcgacgtc attt

54

&lt;210&gt; 34

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide as polylinker based on recognition sequences of SmaI, EcoRI, ScaI, KpnI and SmaI, in this order.

&lt;400&gt; 34

aaattgaatt cgagctcggg acccggg

27

&lt;210&gt; 35

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide as linker based on sequence encoding BglII recognition sequence, two stop codons, and XhoI recognition sequence.

&lt;400&gt; 35

gatcttacta gtaggac

18

&lt;210&gt; 36

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed oligonucleotide as linker based on sequence encoding BglII recognition sequence, two stop codons, and XhoI recognition sequence.

&lt;400&gt; 36

tcgagatcct actagtaa

18